(PubMed) Delaney CL, Spark JI, Thomas J, Wong YT, Chan LT, Miller MD
Here, we provide the first evidence of improved healthspan and age-related survival with a therapeutic mAb by demonstrating that treatment with an IGF-1R antagonist in older mice significantly and preferentially improves several indices of healthspan, reduced death from neoplastic disease, and increased mean and median lifespan in females
NAC may also interact with nitroglycerin, blood thinners and some blood pressure medicines, which is why your doctor may tell you to avoid the supplements
The one bright spot in the clinical data is safety
The study discussed here was relatively small, involving only 17 patients, and more extensive clinical trials are needed to fully understand: Long-term safety profile Optimal dosing protocols Patient selection criteria Potential side effects Interactions with other treatments Additionally, patients should be aware that BPC-157 is not yet FDA-approved for human use, and treatment is typically offered on a research or compassionate use basis by qualified practitioners
10.1007/s11240-014-0458-8 146 ShibuM
